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Aim: It has been thought that hepatocyte growth factor (HGF) levels increase during acute phases of infectious diseases. The aim of this
study was to determine whether HGF, C-reactive protein (CRP), and proinflammatory cytokines have any diagnostic and prognostic
value, and to assess HGF as a biomarker in patients with febrile neutropenia.
Materials and methods: This study included 20 patients with febrile neutropenia as the study group and 20 healthy individuals as
the control group. Serial measurements of serum HGF, CRP, and proinflammatory cytokine levels were performed by enzyme-linked
immunosorbent assay (ELISA) at the baseline, after 48 h of treatment, and at posttreatment.
Results: It was found that HGF levels at the baseline were significantly higher than those in the healthy controls (P = 0.001). It was also
seen that HGF levels 48 h after treatment and at posttreatment were significantly lower than those at the baseline (P = 0.012). High-risk
group patients had higher mean serum HGF levels compared with the low-risk group. It was detected that IL-6 and TNF-α levels at the
baseline were significantly decreased after treatment (P = 0.02 and P = 0.005).
Conclusion: Our findings suggested that serial measurement of serum HGF levels may be an important marker to identify risk levels of
febrile neutropenia and to predict its prognosis.
Key words: Febrile neutropenia, hepatocyte growth factor, CRP, cytokine

1. Introduction
Since bacterial infections are potentially life-threatening in
neutropenic patients, empirical antibiotic therapy should
be started as soon as possible after the onset of fever
without delay in order to obtain microbiological evidence
of the infectious agent (1–3). In particular, identifying
low- and high-risk groups using clinical parameters alone
is not sufficient. Thus, reliable and practical parameters are
needed to diagnose infection and to assess risk. C-reactive
protein (CRP), an acute phase protein, is a well-known
parameter produced after release of proinflammatory
cytokines (4). C-reactive protein concentration rises within
24 h and it is found to be elevated in almost all microbial
infections. However, its reliability as an indicator of
microbial infection is hampered by its low specificity (4).
In recent studies, proinflammatory cytokines have been
evaluated as a parameter for infections and autoimmune
diseases (5). In many studies, interleukin-6 (IL-6) has been
suggested as an important indicator of bacteremia (6,7).
* Correspondence: mdozden@yahoo.com

Hepatocyte growth factor (HGF) is a multifunctional
polypeptide that has growth hormone-like effects
in a majority of tissues in addition to mitogenic and
morphogenic effects on various epithelial and endothelial
cells (8). Hepatocyte growth factor is a heterodimeric
protein constituted from 2 subunits, so-called
hepatopoietin A and scatter factor, with molecular weights
of 34 kDa and 69 kDa, bound by disulfide bonds, and its
organotrophic functions has been widely investigated.
It plays an important role as an organotrophic factor in
the physiological regeneration of the liver, kidneys, and
lungs. Accordingly, it has been thought that it is produced
by mesenchymal cells in response to injury and plays an
essential role in the regeneration of epithelial cells in the
injured organ (9,10). Hepatocyte growth factor is angiogenic
in systemic tissue. Titrations of HGF are correlated with
malignity and metastatic phenotype of certain systemic
cancers (11). It has been shown that HGF is accounted
for by malign cell transformation, proliferation, invasion,
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and metastasis of cancer cells (12,13). It has been reported
that HGF levels are increased in sepsis, inflammatory
pulmonary diseases, and pneumonia (14,15). Although
HGF levels in serum and local fluids have been particularly
investigated in acute and chronic inflammatory diseases,
there are a limited number of studies on HGF levels and its
prognostic value in infectious diseases.
It has been suggested that the determination of serum
HGF, cytokines, and CRP in distinct clinical stages of
febrile neutropenia process, and the identification of the
relationship between these parameters and clinical and
microbiological data, would enable early detection of
risk, and aid the identification of treatment approaches
and prognosis. Therefore, our study aimed to determine
whether HGF, CRP, and proinflammatory cytokines have
diagnostic and prognostic value by serial measurements at
the baseline, 48 h after treatment, and at posttreatment,
and to assess the availability of HGF as a biomarker in
patients with febrile neutropenia.
2. Materials and methods
Included in this study were 20 low- and high-risk patients
who were managed in the Oncology Clinic of Fırat
University, School of Medicine and who developed febrile
neutropenia after chemotherapy. Fever was diagnosed
in patients with a single axillary body temperature
measurement of 38.3 °C or 2 distinct body temperature
measurements of 38.0 °C over 24 h. Neutropenia was
diagnosed when the neutrophil count was greater than
500 /mm3 at presentation or was 500–1000/mm3 but
anticipated to fall below 500/mm3 within the following 48
h (3). The following infection categories were described in
patients: fever of unknown origin, bloodstream infection,
clinically identified infection, and microbiologically
identified infection. In addition, patients were stratified
as those with low and high risk according to the
Multinational Association for Supportive Care in Cancer
(MASCC) score (16). By using a standard data sheet, the
following data were recorded: age, sex, received therapies,
duration of neutropenia or fever, length of hospital stay,
and findings of physical examination. There were 20 agematched healthy volunteers without any known disease
and with normal physical examination and laboratory
findings, who were employed as a healthy control group.
Empiric antibiotic therapy, consisting of a beta-lactam
antibiotic with antipseudomonal activity alone (2 g IV
cefoperazone-sulbactam every 12 h, or 2 g IV piperacillintazobactam every 8 h, or 2 g IV cefepime every 12 h, or
2 g IV ceftazidime every 8 h) or in combination with an
aminoglycoside (1 g IV amikacin every 24 h), was initiated
in patients. Required changes were made in accordance
to new pathogens isolated during therapy, whereas an
antifungal agent was added when fever extended for 5–7
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days. The course of fever and clinical symptoms were
evaluated by daily physical examinations and antibiotic
therapy was discontinued at the appropriate time after
recovery of fever and clinical symptoms caused by
infection. Success was defined as at least 5 days without
fever, absolute neutrophil count greater than 500/mm3, and
recovery of clinical and laboratory findings after regression
of fever. Treatment failure was defined as ongoing fever
despite modifications in antimicrobial therapy, no clinical
recovery, or progression of existing findings and infectionrelated mortality.
Three blood samples were taken from patients in the
study group: at onset of fever (febrile neutropenic phase),
48 h after treatment, and at the period where fever and
neutropenia had ameliorated (recovery period), while
a single blood sample was taken in those in the control
group. Sera were separated from blood samples and
stored at −70 °C until assays. Immunoreactive HGF levels
were measured in sera by the micro-ELISA technique
using commercially available kits in accordance with the
manufacturer’s instructions (Biosource International Inc,
Camarillo, CA, USA). Results were expressed as pg/mL.
Serum IL-1, IL-6, IL-8, and TNF-α levels were evaluated
using the ELISA technique.
This study protocol was approved by the local ethics
committee and all participants were informed about the
study.
SPSS for Windows version 15.0 was used for statistical
analysis. Comparison between HGF and proinflammatory
cytokine levels at baseline and those 48 h after treatment
and at the end of the study was performed by repeated
measures analysis of variance analysis. The Wilcoxon
signed rank test was used for comparison of dichotomous
groups. Fisher’s exact test was used to compare differences
between categorical variables, while the Spearman test was
used for correlation analysis. Student’s t test was used for
the comparison between study and control groups. P <
0.05 was considered statistically significant.
3. Results
The mean age of the study group was 56.4 ± 13.2 (range
23–81) years. Underlying primary disorders were
hematological cancers in 8 patients and solid tumors in 12
patients. It was found that the mean absolute neutrophil
count was 254.8 ± 48.2/mm3, whereas the mean duration
of neutropenia was 4.12 ± 1.06 days and the mean length of
stay was 8.37 ± 2.69 days. Table 1 presents the demographic
characteristics and risk factors of the patients. Pneumonia
and pyelonephritis were the most common infections
among those identified clinically and microbiologically.
In 6 patients with a microbiological diagnosis 8 pathogens
were isolated. Of the strains isolated, 5 (62.5%) were gramnegative bacteria, whereas 2 were (25%) gram-positive
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Table 1. Demographic characteristics and risk factors in patients with febrile neutropenia.
Age (mean, years)

56.4 ± 13.2 (23-81)

Sex (female/male)

11/9

Neutrophil count (mean, mm3)

254.8 ± 48.2

Neutrophil count <100/mm3 (n)

7

Neutrophil count 100–500/mm3 (n)

9

Neutrophil count >500/mm3 (n)

4

Duration of neutropenia (mean, days)

4.12 ± 1.06

Duration of fever (mean, days)

2.6 ± 0.16

Duration of hospitalization (mean, days)

8.37 ± 2.69

The underlying disease (hematological cancer/solid tumor)

8/12

MASCC score (low/high)

8/12

Category of infection (n = 20)
Clinical

6

Microbiological

6

Fever of unknown origin

8

Treatment (n = 20)
Monotherapy

12

Combined therapy

8

Duration of treatment (mean, days)

11.7 ± 3.8

MASCC: Multinational Association for Supportive Care in Cancer

bacteria in addition to 1 (12.5%) Candida sp. Table 2
presents microorganisms isolated from patients with
febrile neutropenia. The control group was composed of
10 females and the same number of males, with a mean
age of 53.4 ± 12.42.
Empirical treatments consisted of a single agent
therapy in 60% of patients and combined therapy in 40%.
In monotherapy, the most commonly used antimicrobial
agent was piperacillin-tazobactam (n = 5), followed
by carbepenems (imipenem and meropenem; n = 4)
and cefoperazone-sulbactam (n = 3). The mean time to
response to fever was 2.6 ± 0.16 days. There were 2 patients
that died during an episode of febrile neutropenia. It was
found that duration of neutropenia was longer (5.8 ±
1.76 days) in patients with microbiologically identified
infection. The mean duration of the recovery period was
5.1 ± 1.08 days. Posttreatment samples were not taken
from the patients who died. Mean serum HGF levels
were 2333.07 ± 474.01 pg/mL at baseline in patients in
the study group, whereas they were 401.44 ± 69.75 pg/
mL in controls (P = 0.001) (Table 3). It was found that
HGF levels 48 after treatment and at posttreatment were
significantly decreased when compared to baseline levels
(Figure). A significant correlation was found between
baseline serum HGF and CRP levels (r = 0.642; P = 0.029).
It was also found that mean serum HGF levels in patients

6.000
5.000
4.000
3.000
2.000
1.000
0
Pretreatment

48 h

Posttreatment

Figure. Mean levels of HGF of patients at the onset, at 48 h, and
at posttreatment

in the high-risk group were significantly higher than those
in the low-risk group (3649.20 ± 954.72 vs. 1601.88 ±
357.27; P = 0.035). However, no significant difference was
detected in mean CRP levels between high- and low-risk
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Table 2. Microorganisms isolated from patients with febrile neutropenia.
Urine
n (%)

Blood
n (%)

Total
n (%)

Gram-negative microorganisms
Escherichia coli
Pseudomonas aeruginosa
Klebsiella spp.

3 (37.5)
2 (25)
1 (12.5)
0 (0)

2 (25)
1 (12.5)
0 (0)
1 (12.5)

5 (52.5)
3 (37.5)
1 (12.5)
1 (12.5)

Gram-positive microorganisms *

0 (0)

2 (25)

2 (25)

Candida spp.

0 (0)

1 (12.5)

1 (12.5)

3 (37.5)

5 (62.5)

8 (100)

Microorganisms

Total
* Staphylococcus and streptococcus.

Table 3. Mean levels of HGF and CRP of patients at the onset, at 48 h and at posttreatment, and control groups.
Febrile neutropenia (n = 20)
Pretreatment

48 h

Posttreatment

HGF (pg/mL)

2333.07 ± 474.01*

1897.66 ± 591.19**

785.75 ± 160.23

CRP (mg/L)

52.5 ± 14.8

19.1 ± 3.5

5.6 ± 0.9

£

Control group (n = 20)
401.44 ± 69.75
2.8 ± 0.3

HGF: Hepatocyte growth factor, CRP: C-reactive protein
* vs. 48 h P = 0.012, posttreatment P = 0.001, ** vs. posttreatment P = 0.028
£
vs. 48 h P = 0.004, posttreatment P = 0.0001

groups. HGF levels were significantly different in patients
with microbiologically identified infection (4815.36
± 862.16 vs. 1769.41 ± 346.2) compared to those not
having a microbiologically identified infection. A positive
correlation was found between fever and HGF levels (r =
0.649; P = 0.026).
It was found that baseline IL-6 levels were significantly
decreased after treatment and there was no significant
difference between levels at posttreatment and those in
the control group (P > 0.05) (Table 4). It was also found
that baseline TNF-α was significantly decreased at 48 h
and at posttreatment (P = 0.005). It was seen that levels
of IL-1 and IL-8 didn’t significantly differ by treatment
(P > 0.05). It was found that TNF-α and IL-6 levels at
baseline were significantly correlated with baseline CRP
levels (P = 0.031). When comparing by risk category, no
difference was observed between the groups for the values
of cytokines and CRP (Table 5).
4. Discussion
Infection-related symptoms and signs may be vague in
patients with febrile neutropenia. Fever is the first symptom
in most neutropenic patients with infection. A careful
evaluation should be undertaken because of the lack of or
reduced inflammatory response in these patients. Several
risk factors have to be taken into consideration in patients
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with febrile neutropenia in order to identify a prognosis.
Although it is a widely used practice to hospitalize and
to give broad-spectrum antibiotics to patients with fever
during episodes of neutropenia, patients in the lowrisk group may be managed on an outpatient basis or by
short durations of hospitalization (17). The use of a rapid
and easy diagnostic test that would identify the risk, is
important (18,19). Among these, the most widely accepted
one is the risk stratification developed by MASCC and used
to discriminate patients as those at low and high risk (16).
The different existing approaches need to be improved as
they do not have satisfactory sensitivity. Thus, reliable and
practical parameters are needed to diagnose infection and
to assess risk. C-reactive protein (CRP) is an acute phase
protein and a well-known parameter produced after the
release of proinflammatory cytokines (4). However, the
reliability of CRP as an indicator of a microbial infection
is diminished due to its low specificity (4). It has been
reported that levels of HGF, a multifunctional protein,
are increased in several infection diseases such as sepsis,
brucellosis, pneumonia, and urinary infections as well as
cancers (14,15).
It is thought that HGF levels are increased during
the acute phase of infection diseases, which reflects
the regeneration process in injured organs (20,21). In
an investigation performed in 60 patients with acute
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Table 4. Mean levels of IL-1, IL-6, IL-8, and TNF-α in patients at the onset, at 48 h and at posttreatment in febrile neutropenia compared
with the control group.
Febrile neutropenia (n=20)

Control group (n=20)

Pretreatment

48 h

Posttreatment

IL-1 (pg/mL)

21.86 ± 3.09

22.20 ± 2.13

22.58 ± 2.11

13.2 ± 5.86

IL-6 (pg/mL)

185.37 ± 46.74 *

178.81 ± 71.68

143.87 ± 26.67

110.6 ± 18.43

Il-8 (pg/mL)

236.50 ± 31.52

225.60 ± 37.9

161.31 ± 11.02

144.32 ± 29.41

TNF-α (pg/mL)

127.68 ± 12.97*

123.92 ± 9.73£

109.87 ± 11.79

110.6 ± 22.80

* vs. posttreatment P = 0.02, £ vs. posttreatment P = 0.005

Table 5. Mean levels of HGF, IL-1, IL-6, IL-8, and TNF-α of patients by risk group.

HGF (pg/mL)

Low-risk (n: 8)

High-risk (n: 12)

3649.20 ± 954.72*

1601.88 ± 357.27

IL-1 (pg/mL)

22.44 ± 3.81

21.11 ± 1.85

IL-6 (pg/mL)

189.66 ± 51.17

179.85 ± 43.68

Il-8 (pg/mL)
TNF-α (pg/mL)

268.55 ± 47.93
129.66 ± 12.73

195.28 ± 35.17
125.14 ± 13.82

* vs. high-risk P = 0.035

myelocytic leukemia, serum concentrations of HGF
were measured and it was found that 28% of the patients
had elevated HGF concentrations, with a correlation
between HGF levels and the presence of disseminated
intravascular coagulation (22). Again, it is proposed that
low HGF levels, reflecting insufficient production, may be
a predictor of a poor prognosis (14,15). In a study of HGF
levels in patients with acute pancreatitis, it was reported
that HGF is similar to CRP, and more useful than IL-6,
in the detection of severe pancreatitis, whereas it is better
than both CRP and IL-6 in prognosis determination (23).
In our patients, serum HGF, cytokines, and CRP levels
were measured 3 times, including during the neutropenic
period without fever after chemotherapy, at the onset of
fever (neutropenic period with fever), at 48 h, and at the
period where fever and neutropenia had ameliorated
(recovery). In our study, mean serum HGF levels were
significantly higher in the study group than in the controls
and there was a significant correlation between baseline
HGF and CRP levels.
There are studies suggesting that procalcitonins and
some cytokines are valuable in the prediction of severe
infections, especially in gram-negative bacteremia (24).
Recent data support this, particularly that procalcitonin
and IL-8 are the most promising biomarkers for

management and prognostication of patients with febrile
neutropenia (25). In a study of procalcitonin, CRP, and
IL-6 levels as indicators for bacteremia in patients with
febrile neutropenia, levels of procalcitonin and IL-6
were significantly higher in patients with bacteremia
than in those without bacteremia, but CRP levels did not
significantly change among groups. Authors suggested
that procalcitonin and IL-6 are more reliable markers
than CRP in the prediction of bacteremia in patients
with febrile neutropenia (26). However, it was found that
procalcitonin levels do not reach high levels in febrile
neutropenia and do not show significant differences in
microbiologically documented cases and in those with
unknown origin of fever (27). In a study of 26 patients,
serum IL-8 levels were found to be higher in patients with
febrile neutropenia when compared to cancer patients
with newly diagnosed fever but no neutropenia, or to
those with infection but no diagnosis of cancer. No such
relationship was found for CRP and procalcitonin (27).
Although HGF levels were found to be low in neutropenia
and neutropenic infections, it was reported that high HGF
levels were correlated with increased early mortality, with
levels normalizing during posttreatment in responders
(22). In our study, serum HGF, IL-6, and TNF-α were
higher before treatment and began to decrease 48 h after
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treatment and approximated to normal control levels in
posttreatment after effective treatment. It was seen that
HGF levels were decreased by the regression of fever
and had a correlation with fever. Particularly, there were
significantly higher HGF levels in patients in the highrisk group when compared to those in the low-risk group,
suggesting that HGF may be a more important biomarker
than other known biomarkers for determination of risk
level and prognostication. Again, significant HGF levels
in our patients with microbiologically identified infection
show that HGF may be an important parameter for
diagnosis in addition to its prognostic value.
It has been reported that levels of IL-8 are increased
in several infectious diseases such as brucellosis and
that high IL-8 value may be an indicator of relapse (28).
Data regarding the duration of antibiotic therapy are
controversial in cases of febrile neutropenia. Particularly,
it has been reported that IL-8 may be a useful marker
in low-risk patients for the discontinuation of antibiotic
therapy. It has been reported that IL-8 may be used in
risk assessment and may be an early indicator of, febrile
neutropenia (29). It was seen that serum TNF-α, IL-1,

IL-6, and IL-8 concentrations are increased in patients
with febrile neutropenia induced by chemotherapy (30).
It was seen that IL-6 and TNF-α levels were significantly
decreased after 48 h and at the end of treatment compared
to baseline levels in our patients with febrile neutropenia.
No significant difference was detected among IL-8 and
IL-1 levels before and after treatment or in the control
group in our study.
This is the first study in which HGF levels were serially
evaluated at different clinical phases in patients with febrile
neutropenia. However, the use of markers such as HGF and
CRP is limited, as patients with febrile neutropenia form a
heterogeneous group in terms of infection and risk score.
In particular, it is expected that biomarkers that would be
used in febrile neutropenia should be as sensitive as and
more specific than fever. It is also known that mortality is
caused by delayed diagnosis and antibiotic therapy rather
than long-term use of antibiotics in patients with febrile
neutropenia. Thus, randomized, controlled studies with
larger sample sizes are needed to determine if HGF can be
used as an early diagnostic tool as well as for prognosis and
risk score in febrile neutropenia.
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